Ninety One UK Ltd Has $95.11 Million Holdings in Natera, Inc. $NTRA

Key Points

• Ninety One UK Ltd increased its stake in Natera, Inc. by 149.1%, owning approximately $95.11 million worth of shares as of the latest SEC filing.
• Natera reported $546.60 million in revenue for the quarter but fell short on EPS, posting a loss of ($0.74) per share, missing expectations by ($0.14).
• Analysts maintain a positive outlook on Natera, with a consensus rating of "Buy" and a price target averaging around $192.88.

Ninety One UK Ltd raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 149.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 562,985 shares of the medical research company's stock after buying an additional 336,985 shares during the quarter. Ninety One UK Ltd owned about 0.41% of Natera worth $95,111,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Guided Capital Wealth Management LLC grew its position in Natera by 0.5% in the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock valued at $2,219,000 after acquiring an additional 66 shares during the period. Fulton Bank N.A. grew its position in Natera by 2.0% in the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after acquiring an additional 71 shares during the period. Wedmont Private Capital grew its position in Natera by 4.9% in the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock valued at $256,000 after acquiring an additional 74 shares during the period. Compound Planning Inc. grew its position in Natera by 4.2% in the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after acquiring an additional 78 shares during the period. Finally, QRG Capital Management Inc. grew its position in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after acquiring an additional 81 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $132.89, for a total value of $398,670.00. Following the transaction, the insider owned 123,059 shares in the company, valued at $16,353,310.51. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 2,496 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the transaction, the director owned 5,763 shares in the company, valued at approximately $767,458.71. This represents a 30.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,781 shares of company stock valued at $6,350,095 over the last 90 days. Corporate insiders own 5.63% of the company's stock.

Natera Stock Performance

Shares of NTRA stock opened at $160.97 on Wednesday. The stock's fifty day moving average is $159.75 and its 200-day moving average is $156.32. The stock has a market capitalization of $22.09 billion, a PE ratio of -84.28 and a beta of 1.68. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Barclays reiterated an "overweight" rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Stephens reiterated an "overweight" rating and issued a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Wells Fargo & Company assumed coverage on Natera in a research report on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price target on the stock. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Natera has a consensus rating of "Buy" and a consensus price target of $192.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.